<?xml version="1.0" encoding="UTF-8"?>
<p id="para0025">Pimodivir is a cyclohexyl carboxylic acid analogue (
 <xref rid="fig0001" ref-type="fig">Fig 1</xref>) that inhibits influenza virus replication by targeting the polymerase PB2 subunit. The drug outperformed current standard-of-care in animal infection models of H3N2 and H1N1 viruses, although potency was highest against H1N1 strains.
 <xref rid="bib0116" ref-type="bibr">
  <sup>116</sup>
 </xref> Also pimodivir remained active against viruses harboring signature resistance mutations to the NAIs,
 <xref rid="bib0117" ref-type="bibr">
  <sup>117</sup>
 </xref> and is presumably at low risk of cross-resistance with baloxavir marboxil as well. The compound was well-tolerated in a phase 2 clinical trial, reduced viral load, and resulted in slightly faster resolve of clinical signs.
 <xref rid="bib0118" ref-type="bibr">
  <sup>118</sup>
 </xref>
</p>
